Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity
Premiere Date: Thursday, June 11, 2020This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, June 11, 2021
Note: Credit Is No Longer Available
 | Fred D. Lublin, MD, FAAN, FANA (Moderator) Saunders Family Professor of Neurology Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Icahn School of Medicine at Mount Sinai New York, NY |
 | Aaron Miller, MD, FAAN, FANA Medical Director Corinne Goldsmith Dickinson Center for Multiple Sclerosis Professor and Vice-Chair for Education Department of Neurology Icahn School of Medicine at Mount Sinai New York, NY |
 | Claire S. Riley, MD Assistant Professor of Neurology Medical Director, Columbia University Mul1ple Sclerosis Center Department of Neurology Columbia University New York, NY |
The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, and clinical data for both show promise for patients with SPMS.
However, despite these advances, studies have shown that gaps in knowledge and performance exist among neurologists and their care team that pose a barrier to the integration of new and emerging therapies to treat MS in clinical practice.
This CME Outfitters Live and On Demand webcast will include an interactive, case-based panel discussion featuring expert faculty who will discuss the symptoms and clinical features of progressive MS, summarize its immunopathology and the mechanisms of action (MOAs) of new and investigational disease modifying therapies (DMTs), and evaluate the latest clinical evidence on the efficacy and safety of new and emerging therapies for SPMS and PPMS.
At the end of this CE activity, participants should be able to:
- Recognize the symptoms and clinic features of progressive MS.
- Summarize the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
- Evaluate the latest clinic evidence of new and emerging therapies for SPMS and PPMS and engage patients in the shared decision-making process.
- Integrate strategies for SDM to deliver patient-centered care.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Recognize the symptoms and clinical features of progressive MS.
- Summarize the immunopathology of progressive MS and the MOAs of new and investigational DMTs.
- Summarize the latest clinical evidence on efficacy and safety of new and emerging therapies for SPMS and PPMS.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Neurologists, MS specialists, PAs, NPs, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-20-094-L01-P
Enduring: 0376-0000-20-094-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Live activity
Enduring material
ABPN MOC Credit:
Note to ABPN Diplomates: ABPN Diplomates may select any activity relevant to their practice to count towards ABPN MOC requirements.
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lublin reports that he receives research support from Actelion Pharmaceuticals; Biogen; Brainstorm Cell Therapeutics Inc; National Institutes of Health (NIH); National Multiple Sclerosis Society (NMSS); Novartis; and Sanofi. He has consulting agreements, serves on advisory boards, or Data and Safety Monitoring Board for Acorda Therapeutics; Actelion Pharmaceuticals/Janssen Pharmaceuticals, Inc.; Apitope; Brainstorm Cell Therapeutics Inc.; Atara Biotherapeutics, Inc.;Avotres; Biogen; EMD Serono, Inc; GW Pharmaceuticals; Immunic, Inc.; Innate Immunotherapeutics; Jazz Pharmaceuticals, Inc.; Mapi Pharma; MedDay Pharmaceuticals; MedImmune/ Viela Bio; Mylan; Novartis; Orion Biotechnology; Polpharma; Receptos, Inc./Celgene Corporation; Roche/Genentech, Inc.; Sanofi/Genzyme Corporation; Teva Pharmaceuticals; The Population Council, Inc. and TG Therapeutics. He is a speaker for Sanofi (non-promotional).
Dr. Miller reports he receives research support from F. Hoffmann-La Roche Ltd/Genentech, Inc.; Mallinckrodt; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; and Sanofi/Genzyme Corporation. He serves as a consultant for AbbVie: Inc.: Accordant Health Services (Caremark); Adamas Pharmaceuticals, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company/Celgene Corporation; Corrona; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt; Mapi-Pharma; and Novartis Pharmaceuticals Corporation. He serves on the speakers' bureau for Alexion Pharmaceuticals, Inc. (unbranded disease awareness programs only); Biogen Idec Inc. (unbranded disease awareness programs only); EMD Serono, Inc. (unbranded journal club); and Genentech, Inc. (unbranded disease awareness programs only).
Dr. Riley reports she receives research support from Biogen Idec Inc. She is a consultant for EMD Serono, Inc.; Genentech, Inc.: Novartis; and TG Therapeutics.
Alaeddin Abukabda, MS, DMD, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-113-061120-45
